#USA #Phoenix #cancer detection #Calviri #StageOne Plus

Calviri's Groundbreaking Diagnostic Test for Dog Cancer Detection

In a significant advancement for veterinary oncology, Calviri, Inc. has announced new results demonstrating their innovative detection method for stage 1 tumors in dogs. Published in the esteemed American Journal of Veterinary Research, this research outlines a diagnostic tool that significantly enhances the ability to detect five major types of canine cancers at their earliest stage, providing a potential lifeline for many pets and their owners.

Calviri, a biotech company committed to fighting cancer in both dogs and humans, has focused on a crucial need in veterinary medicine: the timely detection of cancer. Traditionally, many canine cancers are identified only after they have progressed to later, more severe stages, resulting in lower treatment efficacy and higher medical costs. By enabling the detection of cancers like lymphoma, hemangiosarcoma, osteosarcoma, mast cell tumors, and soft tissue sarcomas at stage 1, Calviri aims to revolutionize the way veterinarians approach canine oncology.

The Importance of Early Detection

Timely cancer diagnosis is essential for improving outcomes in any patient, including beloved dogs. Current technologies often fail to detect cancers early on, leading to late-stage diagnoses when signs become apparent and treatment options are limited. Dr. David Vail, a DVM and professor in Comparative Oncology at the University of Wisconsin, emphasizes the implications of this advancement. He notes that most aggressive cancers in companion animals present in later stages, where available treatments may not yield successful results.

The potential for improved health outcomes through early detection cannot be overstated—especially because roughly 50% of senior dogs (those aged 5 and older) will face a cancer diagnosis during their lifetime. Calviri's new test, named StageOne Plus, represents a critical step forward in maximizing treatment success rates by allowing earlier intervention.

How Does the StageOne Plus Test Work?

The StageOne Plus diagnostic test operates using innovative technology that harnesses the body’s natural immune response. It analyzes the unique antibody repertoire found in a small sample of the patient’s blood, which is then displayed on specialized peptide chips produced internally. This approach integrates semiconductor photolithography with peptide synthesis, making it possible to detect specific tumor markers associated with the cancers in question.

The process requires only a minimal blood sample, thus making it accessible for routine annual wellness exams for dogs. This is especially significant as it will enable owners to screen their pets systematically and to identify any issues before they escalate into emergencies.

Future Availability and Impact

Calviri plans to roll out its StageOne Plus test in select veterinary clinics starting this August, with plans to expand as their testing capabilities grow. The company's commitment to developing this diagnostic test spans four years and reflects a robust dedication to enhancing the quality of veterinary care.

In a statement, Stephen Albert Johnston, the CEO of Calviri, expressed his optimism about the future of canine cancer diagnostics. He remarked, “We are thrilled to have broken the stage 1 sensitivity barrier in detecting dog cancers. Our aim is to provide veterinarians and pet owners with access to this critical diagnostic tool to catch cancer at its earliest stage and ultimately save lives.”

With Calviri’s ambitious efforts to transform canine oncology, the potential impact on pet health and longevity could be substantial, marking a pivotal moment in veterinary medicine.

For additional insights and information about Calviri and its offerings, please visit www.Calviri.com.